"""
Question: 1101 

Evidence: We investigated for the first time the subtype distribution, prevalence of multiple HIV-1 infections, sexual networks, and partnership histories in a cohort of women engaged in high-risk sexual behavior such as female sex workers (FSWs) and women employed in entertainment facilities. The sequences have been deposited into GenBank under accession numbers HQ709446–HQ710484.

Rationale: The paper explicitly states this is the first investigation of these topics in this cohort and provides newly deposited GenBank accessions, indicating the data are previously unpublished.

Answer: Yes
"""

"""
Question: 1102 

Evidence: The purified PCR products were directly sequenced in the sense and antisense directions with primers GP46F2 and GP47R2 for gp-41 and Unipol1 and Unipol2 for pol-IN. The sequences have been deposited into GenBank under accession numbers HQ709446–HQ710484.

Rationale: The methods describe direct sequencing of HIV genes and the results include GenBank deposition, confirming that HIV sequences were reported.

Answer: Yes
"""

"""
Question: 1103 

Evidence: The purified PCR products were directly sequenced in the sense and antisense directions with primers GP46F2 and GP47R2 for gp-41 and Unipol1 and Unipol2 for pol-IN. Phylogenetic analysis and the pairwise evolutionary distances were estimated using the HKY85 model.

Rationale: The study performed PCR, sequencing, and phylogenetic analyses only; there is no mention of in vitro passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: We investigated for the first time the subtype distribution, prevalence of multiple HIV-1 infections, sexual networks, and partnership histories in a cohort of women engaged in high-risk sexual behavior. The purified PCR products were directly sequenced ... for gp-41 and ... for pol-IN.

Rationale: The scope was molecular epidemiology (subtypes, networks, multiple infections) using sequencing; no phenotypic antiretroviral susceptibility testing is described.

Answer: No
"""

"""
Question: 2101 

Evidence: The sequences have been deposited into GenBank under accession numbers HQ709446–HQ710484. 

Rationale: The paper explicitly provides GenBank accession numbers for the sequences.

Answer: Yes
"""

"""
Question: 2102 

Evidence: Blood samples were collected in EDTA tubes from 324 consenting HIV-infected women with unknown seroconversion dates at testing. The sequences have been deposited into GenBank under accession numbers HQ709446–HQ710484.

Rationale: The sequences were obtained from clinical samples from women in the cohort, not laboratory strains, and were deposited in GenBank.

Answer: Yes
"""

"""
Question: 2103 

Evidence: The sequences have been deposited into GenBank under accession numbers HQ709446–HQ710484. 

Rationale: The accession range provided indicates the GenBank identifiers for the sequences.

Answer: HQ709446–HQ710484
"""

"""
Question: 2202 

Evidence: We were able to obtain subtype sequence data for 244 gp-41 (75.3%) and 245 (75.6%) pol -IN out of the 324 individual samples analyzed. The MEGA version 4.0 software package was used to perform phylogenetic analysis.

Rationale: The paper focuses on subtyping and phylogenetics; it does not present per-sample lists of specific mutations.

Answer: No
"""

"""
Question: 2301 

Evidence: We investigated for the first time the subtype distribution, prevalence of multiple HIV-1 infections, sexual networks, and partnership histories in a cohort of women engaged in high-risk sexual behavior. Based on phylogenetic analysis, HIV-1 is classified into three known groups—M, N, and O.

Rationale: The study concerns HIV-1 and its subtypes within group M.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: Of the subtype distribution in the gp -41 gene, 64.3% (n =157) were subtype A, 1.2% (n =3) B, 3.7% (n =9) C, and 30.7% (n =75) D. The overall subtype distribution in both gp -41/ pol -IN genes was 54.3% (n =114) A/A, 2.9% (n =6) C/C, 24.3% (n =51) D/D, 11.9% (n =25) A/D, 4.8% (n =10) D/A, 0.5% (n =1) C/A, 1.0% (n =2) B/A, and 0.5% (n =1) B/D.

Rationale: These sentences enumerate the subtypes and recombinant patterns observed among sequenced viruses.

Answer: Subtypes A, B, C, and D, including intergene recombinants A/D, D/A, C/A, B/A, and B/D.
"""

"""
Question: 2303 

Evidence: Viral RNA was extracted from cryopreserved plasma ... to amplify the gp -41 and pol- IN genes using universal primers. The purified PCR products were directly sequenced ... for gp -41 and ... for pol- IN.

Rationale: The methods explicitly state that gp-41 and pol integrase regions were sequenced.

Answer: gp-41 and pol-IN
"""

"""
Question: 2304 

Evidence: We were able to obtain subtype sequence data for 244 gp -41 (75.3%) and 245 (75.6%) pol -IN out of the 324 individual samples analyzed. The phylogenetic analysis of the pol-IN sequences ... for 245 participants.

Rationale: The paper reports sequencing and analysis results for the pol integrase region.

Answer: Yes
"""

"""
Question: 2401 

Evidence: The Good Health for Women Project (GHWP), a cohort of 1027 women involved in high-risk sexual behavior in Kampala. This is the first study in Kampala, Uganda that describes the subtype distribution of HIV-1 in a cohort of high-risk sexual behavior FSWs.

Rationale: The cohort and sequencing were based in Kampala, Uganda.

Answer: Kampala, Uganda
"""

"""
Question: 2402 

Evidence: The Good Health for Women Project (GHWP) ... was established between March 2008 and April 2009. Blood samples were collected in EDTA tubes from 324 consenting HIV-infected women with unknown seroconversion dates at testing.

Rationale: Samples were collected as part of the cohort established in 2008–2009.

Answer: 2008–2009
"""

"""
Question: 2502 

Evidence: The purified PCR products were directly sequenced in the sense and antisense directions with primers GP46F2 and GP47R2 for gp -41 and Unipol1 and Unipol2 for pol- IN. The cleaned pol- IN secondary PCR products were cloned, and between 10 and 20 positive clones were sequenced.

Rationale: Direct sequencing of PCR products and sequencing of cloned amplicons indicates Sanger sequencing rather than NGS.

Answer: Yes
"""

"""
Question: 2503 

Evidence: The purified PCR products were directly sequenced in the sense and antisense directions with primers ... The cleaned pol- IN secondary PCR products were cloned, and between 10 and 20 positive clones were sequenced.

Rationale: The described methods are consistent with Sanger sequencing; there is no mention of next-generation sequencing.

Answer: No
"""

"""
Question: 2504 

Evidence: The cleaned pol- IN secondary PCR products were cloned, and between 10 and 20 positive clones were sequenced. 

Rationale: This explicitly states that cloning was performed prior to sequencing for a subset of samples.

Answer: Yes
"""

"""
Question: 2505 

Evidence: The cleaned pol- IN secondary PCR products were cloned, and between 10 and 20 positive clones were sequenced. The purified PCR products were directly sequenced in the sense and antisense directions with primers ...

Rationale: The study used cloning and direct (bulk) sequencing; it does not describe single-genome sequencing protocols.

Answer: No
"""

"""
Question: 2506 

Evidence: The cleaned pol- IN secondary PCR products were cloned, and between 10 and 20 positive clones were sequenced. 

Rationale: Cloning of PCR products constitutes molecular cloning.

Answer: Yes
"""

"""
Question: 2601 

Evidence: Viral RNA was extracted from cryopreserved plasma using QIAamp Viral RNA Mini Kit. We were able to obtain subtype sequence data for 244 gp -41 (75.3%) and 245 (75.6%) pol -IN out of the 324 individual samples analyzed.

Rationale: Sequencing was performed on viral RNA extracted from plasma, indicating plasma HIV sequencing results.

Answer: Yes
"""

"""
Question: 2602 

Evidence: Viral RNA was extracted from cryopreserved plasma using QIAamp Viral RNA Mini Kit. 

Rationale: The study used plasma RNA; there is no mention of PBMC-derived DNA/RNA sequencing.

Answer: No
"""

"""
Question: 2603 

Evidence: Blood samples were collected in EDTA tubes from 324 consenting HIV-infected women with unknown seroconversion dates at testing. Viral RNA was extracted from cryopreserved plasma ... We were able to obtain subtype sequence data for 244 gp -41 and 245 pol -IN out of the 324 individual samples analyzed.

Rationale: Plasma viral RNA extraction and sequencing were attempted on all 324 samples; hence 324 underwent plasma virus sequencing attempts.

Answer: 324
"""

"""
Question: 2604 

Evidence: Viral RNA was extracted from cryopreserved plasma using QIAamp Viral RNA Mini Kit. 

Rationale: No PBMC sequencing is described, so the number is zero.

Answer: 0
"""

"""
Question: 2605 

Evidence: Viral RNA was extracted from cryopreserved plasma using QIAamp Viral RNA Mini Kit. We were able to obtain subtype sequence data for 244 gp -41 (75.3%) and 245 (75.6%) pol -IN out of the 324 individual samples analyzed.

Rationale: Sequencing of plasma viral RNA reflects circulating virions (active replication); successful sequencing in many samples indicates presence of active viremia.

Answer: Yes
"""

"""
Question: 2606 

Evidence: Viral RNA was extracted from cryopreserved plasma using QIAamp Viral RNA Mini Kit. 

Rationale: The study did not sequence proviral DNA; it focused on plasma RNA.

Answer: No
"""

"""
Question: 2701 

Evidence: The Good Health for Women Project (GHWP), a cohort of 1027 women involved in high-risk sexual behavior in Kampala. Blood samples were collected ... from 324 consenting HIV-infected women.

Rationale: Participants were adult women; no infants or children were included.

Answer: No
"""

"""
Question: 2702 

Evidence: The Good Health for Women Project (GHWP), a cohort of 1027 women ... was established between March 2008 and April 2009. All consenting women had access to the GHWP clinic offering free ... care ... Women who required initiation of antiretroviral treatment (ART) ... were referred to qualified health centers.

Rationale: This describes an observational cohort with clinical services and referrals, not a clinical trial.

Answer: No
"""

"""
Question: 2703 

Evidence: The Good Health for Women Project (GHWP), a cohort of 1027 women ... All consenting women had access to the GHWP clinic offering free primary and reproductive health care ... Women who required initiation of antiretroviral treatment (ART) ... were referred to qualified health centers.

Rationale: Since it was not a clinical trial, it is not possible that all individuals were in a clinical trial.

Answer: No
"""

"""
Question: 3101 

Evidence: Blood samples were collected in EDTA tubes from 324 consenting HIV-infected women with unknown seroconversion dates at testing. 

Rationale: This is the number of individuals with samples obtained for sequencing.

Answer: 324
"""

"""
Question: 3102 

Evidence: We were able to obtain subtype sequence data for 244 gp -41 (75.3%) and 245 (75.6%) pol -IN out of the 324 individual samples analyzed. Subtype sequence data for both gp -41 and pol -IN were available for 210 (64.8%) individuals.

Rationale: Not all individuals yielded sequencing data; only subsets did.

Answer: No
"""

"""
Question: 4101 

Evidence: The failure to obtain sequence data was either due to failed PCR or failed sequencing probably as a result of low viral loads as some of the women were reported to be on ART. 

Rationale: The paper does not specify which sequences, if any, were from ART-naive individuals; ART status for sequenced individuals is not detailed.

Answer: NA
"""

"""
Question: 4102 

Evidence: The failure to obtain sequence data was ... probably as a result of low viral loads as some of the women were reported to be on ART. 

Rationale: Although some participants were on ART, the paper does not state whether sequences were obtained from those ART-experienced individuals.

Answer: NA
"""

"""
Question: 4103 

Evidence: The failure to obtain sequence data was ... probably as a result of low viral loads as some of the women were reported to be on ART. 

Rationale: The paper does not delineate sequencing results by ART status; thus it is unclear whether both ART-naive and ART-experienced individuals are represented in the sequences.

Answer: NA
"""

"""
Question: 4104 

Evidence: All consenting women had access to the GHWP clinic ... Women who required initiation of antiretroviral treatment (ART) ... were referred to qualified health centers. The failure to obtain sequence data was ... probably as a result of low viral loads as some of the women were reported to be on ART.

Rationale: ART status counts among sequenced individuals are not reported; the number from ART-naive individuals cannot be determined.

Answer: NA
"""

"""
Question: 4105 

Evidence: The failure to obtain sequence data was ... probably as a result of low viral loads as some of the women were reported to be on ART. 

Rationale: The study does not provide complete ART histories for all individuals.

Answer: No
"""

"""
Question: 4201 

Evidence: We investigated ... subtype distribution, prevalence of multiple HIV-1 infections, sexual networks, and partnership histories. 

Rationale: There is no analysis or reporting of transmitted drug resistance prevalence.

Answer: No
"""

"""
Question: 4202 

Evidence: We investigated ... subtype distribution, prevalence of multiple HIV-1 infections, sexual networks, and partnership histories. 

Rationale: Pretreatment drug resistance prevalence is not addressed.

Answer: No
"""

"""
Question: 4301 

Evidence: Women who required initiation of antiretroviral treatment (ART) and other HIV-related care were referred to qualified health centers. 

Rationale: The paper does not specify ART regimens or drug classes received.

Answer: NA
"""

"""
Question: 4302 

Evidence: Women who required initiation of antiretroviral treatment (ART) ... were referred to qualified health centers. 

Rationale: No details are provided about integrase inhibitor use.

Answer: No
"""

"""
Question: 4303 

Evidence: Women who required initiation of antiretroviral treatment (ART) ... were referred to qualified health centers. 

Rationale: No details are provided about protease inhibitor use.

Answer: No
"""

"""
Question: 4304 

Evidence: Women who required initiation of antiretroviral treatment (ART) ... were referred to qualified health centers. 

Rationale: The paper does not describe treatment regimens; it cannot be determined whether all received the same ART.

Answer: NA
"""

"""
Question: 4305 

Evidence: Women who required initiation of antiretroviral treatment (ART) ... were referred to qualified health centers. 

Rationale: The study does not report INSTI exposure status.

Answer: NA
"""

"""
Question: 4403 

Evidence: Women who required initiation of antiretroviral treatment (ART) ... were referred to qualified health centers. 

Rationale: The number of individuals receiving more than one ART regimen is not reported.

Answer: NA
"""

"""
Question: 4404 

Evidence: Women who required initiation of antiretroviral treatment (ART) ... were referred to qualified health centers. 

Rationale: The number receiving more than two ART regimens is not reported.

Answer: NA
"""

"""
Question: 4405 

Evidence: Women who required initiation of antiretroviral treatment (ART) ... were referred to qualified health centers. 

Rationale: The paper provides no regimen counts; therefore, it cannot be determined whether all received the same number of regimens.

Answer: NA
"""

"""
Question: 4406 

Evidence: Women who required initiation of antiretroviral treatment (ART) ... were referred to qualified health centers. 

Rationale: The paper does not report how many received one ART regimen.

Answer: NA
"""

"""
Question: 4501 

Evidence: Women who required initiation of antiretroviral treatment (ART) ... were referred to qualified health centers. 

Rationale: Specific drugs such as dolutegravir are not mentioned.

Answer: NA
"""

"""
Question: 4502 

Evidence: Women who required initiation of antiretroviral treatment (ART) ... were referred to qualified health centers. 

Rationale: Specific drugs such as darunavir are not mentioned.

Answer: NA
"""

"""
Question: 5101 

Evidence: We investigated ... subtype distribution, prevalence of multiple HIV-1 infections, sexual networks, and partnership histories. 

Rationale: The paper does not report analyses of drug resistance mutations.

Answer: NA
"""

"""
Question: 5102 

Evidence: We investigated ... subtype distribution, prevalence of multiple HIV-1 infections, sexual networks, and partnership histories. 

Rationale: No INSTI-resistance mutation data are presented.

Answer: NA
"""

"""
Question: 5103 

Evidence: We investigated ... subtype distribution, prevalence of multiple HIV-1 infections, sexual networks, and partnership histories. 

Rationale: No TDF-resistance mutation data are presented.

Answer: NA
"""

"""
Question: 5104 

Evidence: We investigated ... subtype distribution, prevalence of multiple HIV-1 infections, sexual networks, and partnership histories. 

Rationale: No INSTI resistance mutations are described.

Answer: NA
"""

"""
Question: 6101 

Evidence: We investigated ... subtype distribution, prevalence of multiple HIV-1 infections, sexual networks, and partnership histories. The purified PCR products were directly sequenced ... and ... phylogenetic analysis ...

Rationale: The study performed genotypic/phylogenetic analyses only; no phenotypic susceptibility testing method is reported.

Answer: NA
"""

"""
Question: 6102 

Evidence: We investigated ... subtype distribution, prevalence of multiple HIV-1 infections, sexual networks, and partnership histories. 

Rationale: There are no IC50/IC90 data reported.

Answer: No
"""

"""
Question: 6103 

Evidence: We investigated ... subtype distribution, prevalence of multiple HIV-1 infections, sexual networks, and partnership histories. 

Rationale: No IC50 fold-change data are presented.

Answer: No
"""

"""
Question: 6104 

Evidence: We investigated ... subtype distribution, prevalence of multiple HIV-1 infections, sexual networks, and partnership histories. 

Rationale: No phenotypic susceptibility assay is described.

Answer: NA
"""

"""
Question: 6105 

Evidence: We investigated ... subtype distribution, prevalence of multiple HIV-1 infections, sexual networks, and partnership histories. 

Rationale: The paper does not report replication capacity measurements.

Answer: No
"""

"""
Question: 6106 

Evidence: We investigated ... subtype distribution, prevalence of multiple HIV-1 infections, sexual networks, and partnership histories. 

Rationale: No drugs were tested phenotypically in this study.

Answer: NA
"""

"""
Question: 7101 

Evidence: The cleaned pol- IN secondary PCR products were cloned, and between 10 and 20 positive clones were sequenced. The purified PCR products were directly sequenced ...

Rationale: The study sequenced clinical amplicons; it did not create site-directed mutant isolates.

Answer: No
"""

"""
Question: 7102 

Evidence: The purified PCR products were directly sequenced ... and ... phylogenetic analysis ... We investigated ... subtype distribution, prevalence of multiple HIV-1 infections ...

Rationale: There is no description of in vitro passage experiments; the work involved direct clinical sequencing.

Answer: No
"""